Literature DB >> 30950184

Comparison of the prognostic capability of two comorbidity indices in patients with chronic obstructive pulmonary disease, in real-life clinical practice.

Juan Marco Figueira-Gonçalves1, Rafael Golpe2, Miguel Ángel García-Bello3, Ignacio García-Talavera1, Olalla Castro-Añón2.   

Abstract

BACKGROUND: Comorbidities are a major cause of death in chronic obstructive pulmonary disease (COPD). The COPD-comorbidity test (COTE) index was designed to measure comorbidity burden in this disease. The objective of this study was to compare the capability of COTE and the non-COPD specific Charlson comorbidity index (CCI) to predict all-cause mortality in real-life conditions.
METHODS: Retrospective observational study, carried out in two different series of consecutive COPD patients including, respectively, 790 and 439 subjects. The COTE and non-age-adjusted CCI indices were calculated and the values of the C-statistic for predicting all-cause mortality were compared for both indices.
RESULTS: Median follow-up was 54 months and there were 321 deaths within this period of time. The value of the C-statistic for the CCI was significantly higher than for the COTE index in both groups.
CONCLUSION: When used in real-life clinical practice, the value of the CCI to predict all-cause mortality in COPD seems higher than that of the COTE index.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  COTE index; Charlson comorbidity index; chronic obstructive pulmonary disease; comorbidity; mortality; prognosis

Mesh:

Year:  2019        PMID: 30950184     DOI: 10.1111/crj.13025

Source DB:  PubMed          Journal:  Clin Respir J        ISSN: 1752-6981            Impact factor:   2.570


  2 in total

1.  Baseline characteristics and comorbidities in the CAnadian REgistry for Pulmonary Fibrosis.

Authors:  J H Fisher; M Kolb; M Algamdi; J Morisset; K A Johannson; S Shapera; P Wilcox; T To; M Sadatsafavi; H Manganas; N Khalil; N Hambly; A J Halayko; A S Gershon; C D Fell; G Cox; C J Ryerson
Journal:  BMC Pulm Med       Date:  2019-11-27       Impact factor: 3.317

2.  Suppressor of variegation 3-9 homologue 1 impairment and neutrophil-skewed systemic inflammation are associated with comorbidities in COPD.

Authors:  Tzu-Tao Chen; Sheng-Ming Wu; Kuan-Yuan Chen; Chien-Hua Tseng; Shu-Chuan Ho; Hsiao-Chi Chuang; Po-Hao Feng; Wen-Te Liu; Chia-Li Han; Erick Wan-Chun Huang; Yun-Kai Yeh; Kang-Yun Lee
Journal:  BMC Pulm Med       Date:  2021-10-02       Impact factor: 3.317

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.